In this edition of our Magazine, you can get to know some of the researchers behind our program, for example through a video introducing you to our Biologics Workstream, and an interview with Program Manager Evelien Minten about how Regulatory Innovation is integrated into Oncode Accelerator’s work. You will also meet some of the organizations that we work closely together with, through a dual interview with Tony Hickson, Chief Business Officer for Cancer Research Horizons UK, and Jan Paul Medema, Scientific Director of Oncode Institute.

Our large and diverse community encompasses people with not only a wide range of expertise, but also many different motivations for committing to cancer research and development. In the editorial of the last issue of the Oncode Accelerator Magazine in September 2024, we acknowledged that personal motivations are key to propel us forward in our ambitious and collaborative efforts to positively impact the lives of cancer patients. In this edition, we asked members of our program to share the motivation behind their tireless efforts to outsmart cancer and impact lives. This is what they had to say.

These motivations are a red line through this magazine. For example, one key motivation shared across our community is our commitment to positively impacting the lives of patients. The early-stage, ‘preclinical’ research on which Oncode Accelerator focuses can sometimes seem far removed from impacting patients – but as patient advocate Katell Maguet explains in this issue, there is a close connection between fundamental research and the patient. She says: “It seems disconnected, but it’s not.” 

This interconnection between impact for patients and preclinical research also becomes clear in an article about the introduction of whole genome sequencing for every admitted child at the Princess Máxima Center for pediatric oncology before the start of their treatment. Use of whole genome sequencing can help physicians make faster and more accurate diagnoses, determine the child’s risk level, and choose the best treatment based on their specific genetic alteration. At the same time, this data can help researchers to identify DNA variations underlying the initiation and growth of tumors, to ultimately develop new therapies for children with cancer.

You will also notice our focus on collaboration reappearing throughout this Magazine. We believe that only by bringing together the best and brightest minds in oncology research, can we eventually outsmart cancer and impact lives. As highlighted in this issue, we do this in several ways – for instance by physically bringing together key stakeholders at our annual Oncode Accelerator Summit, by working together with leading organizations like Oncode Institute and Cancer Research Horizons to leverage our complementary strengths, and by supporting excellent scientific research that is published in high-impact journals for others to read and learn from.

As Tony Hickson of Cancer Research Horizons explains, “Bringing clinical innovations to life is a huge challenge, but collaboration helps. By sharing risks and pooling resources, we can achieve more for patients and society.” The importance of collaboration is also reflected in our mission: to collaboratively optimize and accelerate the development of new cancer therapies for the benefit of patients of all ages.

We invite drug developers from academia and industry, and from across the globe, to join us in our mission by applying for Demonstrator Projects. Our current call is open until September 2025, allowing interested parties to apply to access co-funding alongside our unique cancer research ecosystem, comprising state-of-the-art equipment, top scientists from academia and industry, and a dedicated project management team to support the process from start to finish.

As of May 2025, we have already received over 60 applications for Demonstrator Projects from public and private organizations across the globe. In addition, the first two Demonstrator Projects were launched in April 2025. By validating our approach by running these preclinical discovery and development projects within our innovative oncology ecosystem, we can have a lasting impact for both patients and the Dutch economy. This moves us steadily towards our vision for a world where cancer patients can access personalized treatments developed by innovative and integrated R&D ecosystems.